BRAF and ARAF

Data Source:
BioGRID (fluorescent resonance energy transfer, affinity chromatography technology)

		BRAF	ARAF
Description		B-Raf proto-oncogene, serine/threonine kinase	A-Raf proto-oncogene, serine/threonine kinase
Image
GO Annotations	Cellular Component	Nucleus Cytosol Plasma Membrane Intracellular Membrane-bounded Organelle	Cellular_component Mitochondrion Cytosol
	Molecular Function	Protein Kinase Activity Protein Serine/threonine Kinase Activity Calcium Ion Binding Protein Binding ATP Binding Small GTPase Binding Identical Protein Binding Scaffold Protein Binding Protein Serine Kinase Activity Protein Threonine Kinase Activity	Protein Kinase Activity Protein Serine/threonine Kinase Activity MAP Kinase Kinase Kinase Activity Protein Binding ATP Binding Metal Ion Binding Protein Serine Kinase Activity Protein Threonine Kinase Activity
	Biological Process	MAPK Cascade Activation Of MAPKK Activity Protein Phosphorylation Epidermal Growth Factor Receptor Signaling Pathway Animal Organ Morphogenesis Positive Regulation Of Gene Expression Positive Regulation Of Glucose Transmembrane Transport Positive Regulation Of Peptidyl-serine Phosphorylation Negative Regulation Of Apoptotic Process Positive Regulation Of ERK1 And ERK2 Cascade Trehalose Metabolism In Response To Stress Cellular Response To Calcium Ion Establishment Of Protein Localization To Membrane	MAPK Cascade Activation Of MAPKK Activity Cellular Protein Modification Process Protein Phosphorylation Regulation Of TOR Signaling Regulation Of Proteasomal Ubiquitin-dependent Protein Catabolic Process Positive Regulation Of Peptidyl-serine Phosphorylation Negative Regulation Of Apoptotic Process
Pathways		Spry regulation of FGF signaling Frs2-mediated activation Frs2-mediated activation ARMS-mediated activation Signalling to p38 via RIT and RIN RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by MRAS-complex mutants	RAF activation MAP2K and MAPK activation Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by MRAS-complex mutants
Drugs		Sorafenib XL281 RAF-265 PLX-4720 N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime Vemurafenib Regorafenib Dabrafenib Encorafenib Fostamatinib Ripretinib	ATP
Diseases		Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Thyroid cancer Malignant melanoma	Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
GWAS		anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy) ( 31835028) Bipolar disorder ( 31043756) Cerebrospinal fluid t-tau:AB1-42 ratio ( 26252872) Cerebrospinal T-tau levels ( 26252872) Mild influenza (H1N1) infection ( 26379185) Response to Vitamin E supplementation ( 22437554) Type 2 diabetes ( 32499647 28869590)
Interacting Genes		46 interacting genes: AKT1 ARAF AURKA BAD CCDC88A CTSV FBP1 HRAS HSD17B3 ITCH KRAS LATS2 MAP2K1 MAP2K2 MAP2K3 MAP2K6 MAPK1 MAPK3 MRAS NANOG OIP5 PAK2 PEBP1 PPP2CA PPP2R2A PRKACA PRKCE RAF1 RAP1A RAP1GAP RASSF1 RHEB SFN SGK1 SPRY2 STK11 TERF1 TERT UBE2L3 YWHAB YWHAG YWHAH YWHAQ YWHAZ ZNF189 ZNF510	59 interacting genes: AGTRAP AKT1 ASS1 BAD BECN1 BRAF CCND2 CDK4 CDK6 CDKN2B CHD6 COPS3 CPS1 CSNK2B DIDO1 E2F6 EFEMP1 EPHA2 FGFR4 GLIS2 GNA12 HRAS IRAK2 IRF7 KLHL12 KRAS LATS2 MAP2K1 MAP2K2 MAP2K3 MAP2K5 MLH1 MYC MYO18A NELFCD NF2 NRAS NUDT14 PBK PDGFRB PIK3CA PIK3R1 PKM PRPF6 RABGGTB RASSF1 RGS12 RRAS RRAS2 SFN STK11 TEKT4P2 TESK1 TIMM44 TIRAP TP53 TSC1 WNK1 YWHAG
Entrez ID		673	369
HPRD ID		01264	02405
Ensembl ID		ENSG00000157764	ENSG00000078061
Uniprot IDs		P15056	A0A024R178 P10398 Q96II5
PDB IDs		1UWH 1UWJ 2FB8 2L05 3C4C 3D4Q 3IDP 3II5 3NY5 3OG7 3PPJ 3PPK 3PRF 3PRI 3PSB 3PSD 3Q4C 3Q96 3SKC 3TV4 3TV6 4CQE 4DBN 4E26 4E4X 4EHE 4EHG 4FC0 4FK3 4G9C 4G9R 4H58 4JVG 4KSP 4KSQ 4MBJ 4MNE 4MNF 4PP7 4R5Y 4RZV 4RZW 4WO5 4XV1 4XV2 4XV3 4XV9 4YHT 5C9C 5CSW 5CSX 5CT7 5FD2 5HI2 5HID 5HIE 5ITA 5J17 5J18 5J2R 5JRQ 5JSM 5JT2 5VAL 5VAM 5VR3 5VYK 6B8U 6CAD 6N0P 6N0Q 6NSQ 6NYB 6P3D 6P7G 6PP9 6Q0J 6Q0K 6Q0T 6U2G 6U2H 6UAN 6UUO 6XAG	1WXM 2MSE
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?